The possibility of commercializing the first new drug for AI development in 2030...Significantly reduce development time and cost
May 22, 2025
|
Alex Zaboronkov, CEO of Insilico Medicine, told Bloomberg TV that "the first fully designed new drug by AI will be on the market as early as 2030"." "It would be rather surprising if we don't have such a case in the next five to six years," Zaboronkov said, adding that he hopes Insilico, which has more than 40 internal programs, will be the first.
Founded in 2014, Insilico, an AI new drug development company, is conducting molecular design, discovery of new drug candidates, preclinical trials, and clinical trial prediction through an integrated AI platform developed in-house.
No new AI drug has been officially approved so far, but TakedaRelated data will be released this year as pharmaceutical psoriasis treatment is in the final clinical trial stage.
Jaboronkov said AI can drastically reduce the time and cost of developing new drugs, predicting that competition for developing new AI drugs will intensify in the future.
At the keynote speech meeting of 'Bio Korea 2025' held at COEX in Gangnam-gu, Seoul on the 7th, Zaboronkov said, `We believe that a double-targeted treatment that treats aging and diseases at once can be developed through 'Super Intelligence', which means that it can be done without human intervention from target discovery to molecular design and clinical trial design without experts.'
This article was translated by Naver AI translator.
